Cel-Sci Corporation
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trial for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy.

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Peptide Vaccine for Experimental Autoimmune Myocarditis
derG Immunostimulant Prevention/Treatment of HSV Disease
Augmenting innate and vaccine immune response with der-G
Heteroconjugate Vaccines Against Herpes Simplex Virus